Medincell S.A [MEDCL] vs Valneva SE [VLA] Detailed Stock Comparison
Medincell S.A
Euronext
Loading...
Valneva SE
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Medincell S.A wins in 5 metrics, Valneva SE wins in 10 metrics, with 0 ties. Valneva SE appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Medincell S.A | Valneva SE | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 70.64 | N/A |
| Price-to-Book Ratio | N/A | 3.38 | N/A |
| Debt-to-Equity Ratio | -4.11 | 105.63 | Medincell S.A |
| PEG Ratio | 102.70 | -10.22 | Valneva SE |
| EV/EBITDA | -65.76 | -20.10 | Medincell S.A |
| Profit Margin (TTM) | -66.50% | -34.15% | Valneva SE |
| Operating Margin (TTM) | -17.30% | -22.01% | Medincell S.A |
| Return on Equity | 112.65% | -38.02% | Medincell S.A |
| Return on Assets (TTM) | -10.56% | -6.58% | Valneva SE |
| Free Cash Flow (TTM) | $17.81M | $-83.66M | Medincell S.A |
| 1-Year Return | 33.75% | 59.49% | Valneva SE |
| Price-to-Sales Ratio (TTM) | 24.51 | 3.31 | Valneva SE |
| Enterprise Value | $662.22M | $671.64M | Valneva SE |
| EV/Revenue Ratio | 23.88 | 3.42 | Valneva SE |
| Gross Profit Margin (TTM) | N/A | 50.10% | N/A |
| Revenue per Share (TTM) | $1 | $1 | Valneva SE |
| Earnings per Share (Diluted) | $-0.62 | $-0.46 | Valneva SE |
| Beta (Stock Volatility) | 1.11 | 1.01 | Valneva SE |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Medincell S.A vs Valneva SE Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Medincell S.A | 2.99% | 6.15% | 19.49% | 25.15% | 43.82% | 22.01% |
| Valneva SE | -1.56% | 14.40% | -13.47% | 85.17% | 23.10% | 89.18% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Medincell S.A | 33.75% | 298.51% | 212.87% | 191.16% | 191.16% | 191.16% |
| Valneva SE | 59.49% | -16.28% | -36.20% | 35.71% | -15.47% | -15.47% |
News Based Sentiment: Medincell S.A vs Valneva SE
Medincell S.A
News based Sentiment: POSITIVE
September was a pivotal month for Medincell, highlighted by promising clinical data for both UZEDY® and Olanzapine LAI, coupled with strategic board appointments and continued investor engagement. These developments reinforce the company’s growth trajectory and position it favorably for future success, making it a significant month for investors.
Valneva SE
News based Sentiment: NEGATIVE
September was a critical month for Valneva, marked by the severe consequences of the IXCHIQ vaccine suspension, including significant stock declines, legal investigations, and downward revisions to financial forecasts. While the Q2 earnings beat offered a brief respite, the overarching narrative is one of substantial challenges and increased risk for investors.
Performance & Financial Health Analysis: Medincell S.A vs Valneva SE
| Metric | MEDCL | VLA |
|---|---|---|
| Market Information | ||
| Market Cap | €656.19M | €649.14M |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 132,874 | 1,037,300 |
| 90 Day Avg. Volume | 98,929 | 2,145,825 |
| Last Close | €22.04 | €4.30 |
| 52 Week Range | €12.00 - €22.04 | €1.73 - €5.41 |
| % from 52W High | 0.00% | -20.59% |
| All-Time High | €22.04 (Sep 23, 2025) | €29.70 (Nov 29, 2021) |
| % from All-Time High | 0.00% | -85.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 3.86% | 0.27% |
| Quarterly Earnings Growth | N/A | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | -0.67% | -0.34% |
| Operating Margin (TTM) | -0.17% | -0.22% |
| Return on Equity (TTM) | 1.13% | -0.38% |
| Debt to Equity (MRQ) | -4.11 | 105.63 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €-0.50 | €1.12 |
| Cash per Share (MRQ) | €2.17 | €0.97 |
| Operating Cash Flow (TTM) | €19.47M | €-11,900,000 |
| Levered Free Cash Flow (TTM) | €4.74M | €-34,380,124 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Medincell S.A vs Valneva SE
| Metric | MEDCL | VLA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 70.64 |
| Forward P/E | 102.70 | -10.22 |
| PEG Ratio | 102.70 | -10.22 |
| Price to Sales (TTM) | 24.51 | 3.31 |
| Price to Book (MRQ) | N/A | 3.38 |
| Market Capitalization | ||
| Market Capitalization | €656.19M | €649.14M |
| Enterprise Value | €662.22M | €671.64M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 23.88 | 3.42 |
| Enterprise to EBITDA | -65.76 | -20.10 |
| Risk & Other Metrics | ||
| Beta | 1.11 | 1.01 |
| Book Value per Share (MRQ) | €-0.50 | €1.12 |
Financial Statements Comparison: Medincell S.A vs Valneva SE
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MEDCL | VLA |
|---|---|---|
| Revenue/Sales | N/A | €49.23M |
| Cost of Goods Sold | N/A | €23.04M |
| Gross Profit | N/A | €26.19M |
| Research & Development | N/A | €14.95M |
| Operating Income (EBIT) | N/A | €-5.96M |
| EBITDA | N/A | €-5.45M |
| Pre-Tax Income | N/A | €-7.76M |
| Income Tax | N/A | €1.47M |
| Net Income (Profit) | N/A | €-9.23M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MEDCL | VLA |
|---|---|---|
| Cash & Equivalents | €59.04M | €152.99M |
| Total Current Assets | €80.62M | €287.05M |
| Total Current Liabilities | €29.87M | €106.20M |
| Long-Term Debt | €51.46M | €188.74M |
| Total Shareholders Equity | €-16.37M | €175.25M |
| Retained Earnings | €-18.44M | €-573.16M |
| Property, Plant & Equipment | €7.80M | €154.31M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MEDCL | VLA |
|---|---|---|
| Operating Cash Flow | N/A | €-7.74M |
| Capital Expenditures | N/A | €-1.40M |
| Free Cash Flow | N/A | €-9.62M |
| Debt Repayment | N/A | €-685,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MEDCL | VLA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 132,874 | 1,037,300 |
| Average Daily Volume (90 Day) | 98,929 | 2,145,825 |
| Shares Outstanding | 33.06M | 162.40M |
| Float Shares | 24.75M | 126.75M |
| % Held by Insiders | 0.38% | 0.12% |
| % Held by Institutions | 0.31% | 0.23% |
Dividend Analysis & Yield Comparison: Medincell S.A vs Valneva SE
| Metric | MEDCL | VLA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |